Project I.D.E.F.I.X
-
EIC Transition 2022

I.D.E.F.I.X project, a Multiorgan Toxicity and Efficacy Test Platform as a New Standard as an Alternative to Animal Experimentation

Explore how the I.D.E.F.I.X project aims to revolutionize preclinical testing by providing a groundbreaking alternative to animal experimentation.

Objectives

Develop the I.D.E.F.I.X. project platform from proof-of-concept (TRL3/4) to a viable demonstrator (TRL6)
Qualify the new platform with known drugs in a relevant environment with industrial and academic end-users using three different applications: type 2 diabetes, liver toxicity, and breast cancer.
Make our MPS Disposable prototype into a product.

Our Role

As project sole partner and leader, Cherry Biotech will implement the project. The IDEFIX project will run for 30 months to further develop, integrate, and validate the new microfluidic IDEFIX modular platform with external KOL partners. Divided into 4 interconnected work packages, its pathway to deployment is briefly described thereafter

Work Package 1: I.D.E.F.I.X. project Modular Platform Maturity Development
Work Package 2: Pre-Validation in-house and Qualification in Relevant Environments
Work Package 3: Go-to-market and business strategy preparation
Work Package 4: Management, IP, and dissemination

Expected Results

Design an architechture platform (hardware and software) intergrating the previously developped stackable modules for Gas mixer, Flow, Temperature, Biosensing, Microscope & Imaging control

I.D.E.F.I.X. project platform demonstration and qualification in relevant industrial and hospital environments using respective biological models and known drugs

Finalise the business model by compiling information from stakeholders, distributors and customers. Finalizing the investment readiness plan

This project has been funded by The European Union, under the grant agreement n° 101099775.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

Other Collaborations